Phase II trial of N-methylformamide in advanced renal cancer

J. S. Abrams; N. Tait; H. Silva; M. Eisenberger; D. A. Van Echo; I. N. Olver; J. Aisner

doi:10.1097/00000421-198902000-00009

Phase II trial of N-methylformamide in advanced renal cancer

J. S. Abrams, N. Tait, H. Silva, M. Eisenberger, D. A. Van Echo, I. N. Olver, J. Aisner

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

N-methylformamide (NMF) (800-1,000 mg/m² i.v. day 1) was given to 14 patients with measurable, advanced renal cell carcinoma in this Phase II trial. Treatment was repeated every 28 days. Significant toxicities included drug-induced hepatitis along with moderate nausea and vomiting. No objective responses were seen although several patients had stable disease with treatment for prolonged periods. NMF is not an active agent in renal cell cancer when administered by this schedule.

Original language	English (US)
Pages (from-to)	41-42
Number of pages	2
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	12
Issue number	1
DOIs	https://doi.org/10.1097/00000421-198902000-00009
State	Published - Jan 1 1989
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-198902000-00009

Cite this

@article{dac3a4e5295c41278ef5c61fdc8a5be3,

title = "Phase II trial of N-methylformamide in advanced renal cancer",

abstract = "N-methylformamide (NMF) (800-1,000 mg/m2 i.v. day 1) was given to 14 patients with measurable, advanced renal cell carcinoma in this Phase II trial. Treatment was repeated every 28 days. Significant toxicities included drug-induced hepatitis along with moderate nausea and vomiting. No objective responses were seen although several patients had stable disease with treatment for prolonged periods. NMF is not an active agent in renal cell cancer when administered by this schedule.",

author = "Abrams, {J. S.} and N. Tait and H. Silva and M. Eisenberger and {Van Echo}, {D. A.} and Olver, {I. N.} and J. Aisner",

year = "1989",

month = jan,

day = "1",

doi = "10.1097/00000421-198902000-00009",

language = "English (US)",

volume = "12",

pages = "41--42",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Phase II trial of N-methylformamide in advanced renal cancer

AU - Abrams, J. S.

AU - Tait, N.

AU - Silva, H.

AU - Eisenberger, M.

AU - Van Echo, D. A.

AU - Olver, I. N.

AU - Aisner, J.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - N-methylformamide (NMF) (800-1,000 mg/m2 i.v. day 1) was given to 14 patients with measurable, advanced renal cell carcinoma in this Phase II trial. Treatment was repeated every 28 days. Significant toxicities included drug-induced hepatitis along with moderate nausea and vomiting. No objective responses were seen although several patients had stable disease with treatment for prolonged periods. NMF is not an active agent in renal cell cancer when administered by this schedule.

AB - N-methylformamide (NMF) (800-1,000 mg/m2 i.v. day 1) was given to 14 patients with measurable, advanced renal cell carcinoma in this Phase II trial. Treatment was repeated every 28 days. Significant toxicities included drug-induced hepatitis along with moderate nausea and vomiting. No objective responses were seen although several patients had stable disease with treatment for prolonged periods. NMF is not an active agent in renal cell cancer when administered by this schedule.

UR - http://www.scopus.com/inward/record.url?scp=0024532432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024532432&partnerID=8YFLogxK

U2 - 10.1097/00000421-198902000-00009

DO - 10.1097/00000421-198902000-00009

M3 - Article

C2 - 2912020

AN - SCOPUS:0024532432

SN - 0277-3732

VL - 12

SP - 41

EP - 42

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 1

ER -

Phase II trial of N-methylformamide in advanced renal cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this